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The exquisite control of growth factor function by
heparan sulfate (HS) is dictated by tremendous
structural heterogeneity of sulfated modifications.
How specific HS structures control growth factor-
dependent progenitor expansion during organogen-
esis is unknown. We isolated KIT+ progenitors from
fetal salivary glands during a stage of rapid progeni-
tor expansion and profiled HS biosynthetic enzyme
expression. Enzymes generating a specific type of
3-O-sulfated-HS (3-O-HS) are enriched, and fibro-
blast growth factor 10 (FGF10)/FGF receptor 2b
(FGFR2b) signaling directly regulates their expres-
sion. Bioengineered 3-O-HS binds FGFR2b and
stabilizes FGF10/FGFR2b complexes in a receptor-
and growth factor-specific manner. Rapid autocrine
feedback increases 3-O-HS, KIT, and progenitor
expansion. Knockdown of multiple Hs3st isoforms
limits fetal progenitor expansion but is rescued with
bioengineered 3-O-HS, which also increases adult
progenitor expansion. Altering specific 3-O-sulfated
epitopes provides a mechanism to rapidly respond
to FGFR2b signaling and control progenitor expan-
sion. 3-O-HS may expand KIT+ progenitors in vitro
for regenerative therapy.
INTRODUCTION
During organogenesis, fibroblast growth factor receptor 2b
(FGFR2b) signaling is essential for progenitor survival and prolif-
eration in the submandibular gland (SMG), lung, pancreas, tooth,
and skin (De Moerlooze et al., 2000; Petiot et al., 2003). It is well
established that heparan sulfate (HS) proteoglycans are core-
ceptors for FGFR2b (Mohammadi et al., 2005) and that specific
HS structures are critical for FGFR2b-dependent proliferation
(reviewed in Patel and Hoffman, 2014; Patel et al., 2006). The ge-
netic deletion of HS biosynthetic enzymes highlights that HS is
essential for organogenesis (Bishop et al., 2007). Due to the662 Developmental Cell 29, 662–673, June 23, 2014 ª2014 Elsevier Itremendous variation in sulfate modifications of HS, the sulfo-
transferase enzymes provide an attractive mechanism to in-
crease the cellular specificity to HS-binding growth factors and
to fine-tune the biological responses to FGFR2b signaling.
The HS 3-O-sulfotransferase (Hs3st) family is the largest family
of sulfotransferase enzymes, with seven isoforms in mice and
humans. However, 3-O-sulfation is the least abundant sulfate
modification and occurs at the terminal step of HS biosynthesis
within the Golgi. Although all seven isoforms add a 3-O-sulfate,
they generate two types of modifications (Lawrence et al.,
2007; Xu et al., 2008). The first, termed Hs3st1-like activity, oc-
curs when Hs3st1 adds a sulfate to a glucosamine adjacent to
either a glucuronic or an iduronic acid in the HS chain. This
well-studied type of 3-O-sulfated modification occurs in the anti-
thrombin (AT)-binding pentasaccharide (Lindahl et al., 1980). The
second, termed Hs3st3-like activity, occurs when Hs3st iso-
forms Hs3st2, Hs3st3a1, Hs3st3b1, Hs3st4, or Hs3st6 add
a 3-O-sulfate to a glucosamine adjacent to a 2-O-sulfated idur-
onic acid. For example, this forms a cell surface HS epitope
that allows herpes simplex virus 1 (HSV-1) entry (Shukla et al.,
1999). Lastly, Hs3st5 can generate both types of modifications
(Liu and Pedersen, 2007).
Only two of the Hs3st enzymes have been genetically deleted
in mice. Loss of Hs3st1 results in postnatal lethality with intra-
uterine growth retardation (HajMohammadi et al., 2003), and
mice deficient in Hs3st2 are viable (Hasegawa and Wang,
2008). Hs3st enzymes have distinct roles in other organisms.
For instance, in Drosophila melanogaster a reduction of Hs3st-B
affects neurogenesis (Kamimura et al., 2004); in Caenorhabditis
elegans hst-3.1 and hst-3.2 mediate neurite branching (Tecle
et al., 2013); and in Danio rerio Hs3st5 controls cilia length,
Hs3st6 regulates cell motility (Neugebauer et al., 2013), and
Hs3st7 regulates cardiac contraction (Samson et al., 2013).
However, the specific roles of the Hs3st3 isoforms during
mammalian development are unknown.
Recently, we reported that the highly proliferative distal end
buds of SMGs and lungs contain progenitors expressing the
KIT receptor and FGFR2b and that combined KIT/FGFR2b
signaling is critical for their maintenance and expansion
(Lombaert et al., 2013). Here we discover that KIT+ epithelial
progenitors preferentially synthesize Hs3st3-modified HS to
rapidly increase FGFR2b-mediated signaling and proliferation.nc.
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upregulate Hs3st3 and Kit expression. We propose that 3-O-
HS controls the FGFR2b-dependent expansion of KIT+ progen-
itors during organogenesis and during the in vitro expansion of
adult progenitors.
RESULTS
KIT+ Epithelial Cells Are Enriched in Hs3st3a1 and
Hs3st3b1 Transcripts, and 3-O-Sulfated HS Is Localized
in KIT+ Epithelial End Buds
Because HS is required for high-affinity binding of FGF10 to
FGFR2b, we hypothesized that a progenitor-specific HS modifi-
cation on proteoglycans controlled FGFR2b-dependent prolifer-
ation. We first screened the HS biosynthetic enzyme expression
in SMG epithelium and mesenchyme at embryonic day (E) 13, to
identify which enzymes were expressed in the epithelium (Fig-
ure 1A). Transcripts for Hs3st1, Hs3st3a1, Hs3st3b1, and
Hs3st6 were predominantly in epithelia, whereas Hs3st2,
Hs3st4, and Hs3st5 were in the mesenchyme. Other HS biosyn-
thetic enzymes, such as Hs2st1, Hs6st1, and Ndst1, were
equally expressed in both compartments. Cdh1 and Fgf10
served as controls for the separation of the epithelium and
mesenchyme, respectively. We then used KIT and E-cadherin
(ECAD) antibodies via fluorescence-activated cell sorting
(FACS) to sort the epithelial KIT+ progenitors, which are mainly
localized in the end buds in E13 SMGS (Figure 1B). We profiled
the expression of HS biosynthetic enzymes in the KIT+ECAD+
and KITECAD+ cell populations using quantitative PCR
(qPCR). Interestingly, the FACS-sorted KIT+ cells showed
increased expression of specific HS-3-O-sulfotransferase iso-
forms, Hs3st3a1 and Hs3st3b1, compared to KIT cells. We
confirmed that KIT+ cells are enriched for genes associated
with proliferation and FGFR signaling by the increase in Ccnd1,
Fgfr1b, and the downstream targets of FGFR signaling Etv4,
Etv5, and Myc (Figure 1B). We screened HS proteoglycan core
proteins in the KIT+ cells, and although some were enriched,
none were significantly increased in expression (Figure S1A
available online). These data indicate that the highly proliferating
KIT+ECAD+ progenitors express a unique set of sulfotransferase
enzymes.
Whole-mount in situ analysis of E13 SMGs confirmed the
localization of Hs3st1, Hs3st3a1, and Hs3st3b1 in epithelial
end buds, and Hs6st1 in both the epithelium and mesenchyme
(Figures 1C and S1B). Hs3st6 was barely detectable by qPCR,
and we were unable to detect it by in situ analysis (data not
shown). We also analyzed the temporal expression of the
Hs3st enzymes throughout SMG development by qPCR (Fig-
ure S1C). Hs3st1, Hs3st3a1, and Hs3st3b1 were more abundant
early in SMG development when KIT+ progenitors proliferate to
increase organ size. By comparing the expression with other
fetal organs at E12, including the heart, kidney, liver, limb,
lung, and brain (Figure S1D), distinct tissue-specific expression
patterns of 3-O-sulfotransferases were apparent. For example,
Hs3st4 and Hs3st5 were highly expressed in the brain, whereas
Hs3st6 was high in the kidney (Figure S1D).
Next, it was important to confirm that 3-O-HS was present
on SMG epithelial cells (Figures 1D and 1E). We incubated
SMGswith fluorescent Alexa 488-labeled AT (AT488), which rec-Develognizes the 3-O-HS pentasaccharide epitope generated by the
Hs3st1 enzyme (Girardin et al., 2005). We also incubated
SMGs with a truncated ectodomain of HSV-1gD, which binds
to the Hs3st3-modified HS (Krummenacher et al., 1999; Shukla
et al., 1999). Both AT488 and HSV-1gD specifically labeled HS
on the SMG epithelial cell surface. Pretreatment with hepariti-
nase III (HPT) specifically abolished labeling, whereas chondroi-
tinase ABC (CHABC), which removes chondroitin sulfates, did
not (Figures 1D and 1E). In addition, incubation with excess
AT-binding pentasaccharide or unlabeled AT competed the
AT488 binding (not shown). Taken together, we show that
Hs3st enzymes are specifically localized to epithelial end buds
that contain the KIT+ progenitors and that 3-O-HS is present
on their cell surface.
Hs3st3 Expression Is Directly Regulated by FGFR2b
Signaling
We then investigated whether either FGF10/FGFR2b or KIT
signaling directly regulates the expression of Hs3st isoforms.
Isolated epithelia were treated with FGF10 for 1, 2, and 4 hr,
and Hs3st isoform expression was measured by qPCR. No
morphological differences in the treated epithelium were
observed at these short time points (Figure 2A). Surprisingly,
Hs3st3a1 and Hs3st3b1 expression increased by 2 hr, and by
4 hr Hs3st3a1 expression increased 7-fold. By 4 hr, the expres-
sion of Hs3st1 and Hs3st6 had also increased. As expected,
Myc, an early response gene of FGF10/FGFR2b signaling,
increased within 1 hr, whereas the expression of Ndst1,
Hs2st1, and Hs6st1 did not change during this time (Figure 2A).
We also confirmed that the expression of Kitl increased at 4 hr,
whereas Kit did not, as previously shown (Lombaert et al.,
2013). Importantly, the increase in 3-O-sulfotransferase genes
occurred more rapidly than Etv5, a known downstream target
of FGF10/FGFR2b signaling.
To identify the downstream signaling pathway regulating
Hs3st expression, isolated epithelia were treated for 4 hr with
FGF10 and either an FGFR inhibitor (SU5402), recombinant
FGFR2b, a mitogen-activated protein kinase (MAPK) inhibitor
(UO126), a phosphatidylinositol 3-kinase (PI3K) inhibitor
(LY294002), or a KIT inhibitor ([4-t-butylphenyl]-N-(4-imidazol-
1-yl phenyl)sulfonamide [ISCK03]) (Figure 2B). As predicted, no
morphological differences were observed, but there was
reduced expression of Hs3st3a1 and Hs3st3b1 in epithelia
treated with the FGFR inhibitor, recombinant FGFR2b, and
MAPK inhibitor, but not with the PI3K or KIT inhibitors (Figure 2B).
There was also reduced expression of Etv4, Etv5, Ccnd1, Myc,
Kit, and Kitl with recombinant FGFR2b and MAPK inhibitors
and reduced expression of Etv4 with the PI3K and FGFR inhibi-
tors. The specific KIT inhibitor did not affect the expression of
any genes except for Kitl at 4 hr.
Although KIT signaling did not directly regulateHs3st3 expres-
sion, we previously reported that a reduction in KIT signaling
in vivo diminishes organ growth by depleting KIT+ progenitors
(Lombaert et al., 2013). Therefore, we analyzed the expression
ofHs3st3a1 andHs3st3b1 in E13 SMGs from KitW/Wmice, which
have a mutation in KIT that inhibits signaling, as well as SMGs
treated with the KIT inhibitor for 24 hr. In both situations, there
was a decrease in branching morphogenesis (Figure 2C) and
reduced expression of Hs3st3a1 and Hs3st3b1 (Figure 2D).opmental Cell 29, 662–673, June 23, 2014 ª2014 Elsevier Inc. 663
Figure 1. KIT+ Epithelial End Bud Progenitors Are Enriched for HS 3-O-Sulfotransferase Expression, and 3-O-HS Is Localized in the Epithelial
End Buds
(A) qPCR analysis of isolated E13 SMG epithelia and mesenchyme. Gene expression was normalized to Rps29.
(B) The expression levels of HS biosynthetic enzymes were compared by qPCR in cDNA from the KIT+ versus KITECAD+ FACS-sorted cells. Gene expression
was normalized to expression in the KIT cells andRps29. A false discovery rate (Q) for multiple unpaired t tests was set to 5%. *p% 0.05, **p% 0.01, and ***p%
0.001. Error bars represent SEM. Images are single confocal projection with KIT (red) and perlecan (pink) labeling in an E13 SMG. Scale bar, 200 mm. FACS plot
shows the percentage of KIT+ECAD+ cells (red box) and KITECAD+ cells (green box) sorted from E13 SMGs.
(C) Sections of whole-mount in situ analysis of E13 SMG confirm the localization of Hs3st isoforms in the end bud (dotted line); counterstained with nuclear
fast red.
(D) Staining of E13 SMGs with labeled AT (AT488, green). HPT but not CHABC treatment for 2 hr abolished AT488 labeling. Perlecan (blue) localized in the
basement membrane, and ECAD (red) labeled the epithelium. Images are single confocal sections. Scale bar, 20 mm.
(E) Staining with HSV-1 gD285 protein localized Hs3st3-type 3-O-HS at the epithelial cell surface. HPT treatment also decreased binding of HSV-1gD (green).
Perlecan (blue) and TGFBR3 (red), which stains the epithelium, are shown. Images are single confocal sections. Scale bar, 5 mm.
Error bars show SEM. See also Figure S1.
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compared to the wild-type glands, suggesting that in vivo
compensation with other Hs3st isoforms may occur. Overall,
these data suggest that an FGF10/FGFR2b-mediated MAPK
pathway rapidly and directly regulates Hs3st3 expression and
that the reduced proliferation by loss of KIT signaling correlates
with reduced levels of Hs3st3s.664 Developmental Cell 29, 662–673, June 23, 2014 ª2014 Elsevier I3-O-Sulfated HS Binds FGFR2b to Enhance 3-O-HS/
FGF10/FGFR2b Ternary Complex Formation and
Proliferation
In order to investigate the molecular mechanism of how 3-O-HS
could rapidly control progenitor expansion, we bioengineered
HS with 3-O-sulfated epitopes generated by different Hs3st en-
zymes. We used HS isolated from bovine kidney, because it hasnc.
Figure 2. Hs3st Expression Is Rapidly
Regulated by FGFR2b-Dependent MAPK
Signaling and Is Reduced When KIT
Signaling Is Reduced
(A) Isolated E13 epithelia (inset) were treated with
400 ng/ml FGF10 for 1, 2, or 4 hr, which does not
affect morphogenesis. Gene expression was
normalized to epithelium at 0 hr and Rps29.
(B) SMGs (E13) were treated for 4 hr with an FGFR
inhibitor (SU5402, 5 mM), recombinant FGFR2b
(25 nM), a MAPK inhibitor (UO126, 20 mM), a PI3K
inhibitor (LY294002, 25 mM), and an SCF/KIT
inhibitor (ISCK03, 20 mM). qPCR analysis was
normalized to DMSO or recombinant (r)FGFR1b (a
control for rFGFR2b). No morphological changes
wereobservedbetween treatmentsafter 4hr (inset).
(C) Inhibition of KIT signaling in SMGs with a KIT
inhibitor (ISCK03, 20 mM) or in vivo using E14
KitW/W mice reduced SMG branching morpho-
genesis compared to controls. The bud count was
normalized (%) to control. Scale bar, 200 mm.
(D) SMGs (E13) either treated with a KIT inhibitor
(ISCK03, 20 mM) for 24 hr or isolated from E13
KitW/Wmice have reduced expression of Hs3st3a1
and Hs3st3b1. Gene expression was normalized
to DMSO-carrier control or wild-type control and
Rps29.
Error bars show SEM. ANOVA (A and B) and
Student’s t test (C and D); *p < 0.05, **p < 0.01,
and ***p < 0.001.
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kidney HS (simply termed HS here) was treated with recombi-
nant Hs3st1 and Hs3st3 enzymes to generate two types of
3-O-HS, denoted as 3st1-HS and 3st3-HS, respectively (Fig-
ure S2A). The enzymatic treatment wasmonitored by radioactive
sulfate incorporation, and only one or two 3-O-sulfates were
added per 14 kDa HS chain, that had, on average, 48 sulfates/
chain, thereby increasing overall sulfation by only 2%–4% (see
Supplemental Experimental Procedures and Xu et al., 2008).
The current model of an HS/FGF10/FGFR2b ternary signaling
complex predicts that HS could function to promote FGFR2b
dimerization, stabilize the interactions of FGF10 with the recep-
tor, and/or stabilize direct receptor-receptor contacts (Moham-
madi et al., 2005). We used a variety of biochemical assays to
define how 3-O-HS functions.
To determine whether 3-O-HS could bind to either FGFR2b or
FGF10, a solid-phase HS-binding assay was used. The 3-O-HSDevelopmental Cell 29, 662–6was immobilized in glycosaminoglycan
(GAG) binding plates, and recombinant
FGFR2b-Fc or FGF10 was added.
Binding was measured with an anti-Fc
antibody to detect FGFR2b or an anti-
FGF10 antibody. Heparin, which binds
both FGFR2b and FGF10 and is highly
sulfated (including 3-O-sulfation), was
used as a positive control, and chon-
droitin sulfate A was used as a negative
control. We observed increased FGFR2b
binding to 3st3-HS compared to 3st1-HS
or HS (Figure 3A). As expected, recombi-nant FGFR1b did not bind to HS (Figure 3A). FGF10 also did not
bind to the immobilized 3-O-HS any more than chondroitin
sulfate (Figure 3B), even at concentrations 10-fold higher than
that used for FGFR2b binding. Heparin decasaccharides that
increase FGF10 bioactivity (Patel et al., 2008) were used as a
positive control for FGF10 binding and bound more FGF10
than FGFR2b (Figure 3B). These data suggest that 3-O-HS pref-
erentially interacts with FGFR2b and not FGF10.
To determine whether 3-O-HS stabilizes FGF10/FGFR2b
complex formation, equimolar amounts of recombinant
FGFR2b, FGF10, and HS were mixed, and then FGFR2b was
immunoprecipitated and blotted for both FGFR2b and FGF10.
As expected, HS increased the ternary complex formation and
more FGF10 was detected, compared to when HS was not
added. However, the addition of either 3st1-HS or 3st3-HS
further increased the amount of FGF10 pulled down in the
complex (Figure 3C). This shows that 3-O-HS enhances the73, June 23, 2014 ª2014 Elsevier Inc. 665
Figure 3. 3st3-HS Preferentially Binds FGFR2b to Increase Ternary Complex Formation of FGF10/FGFR2b and Proliferation of FGFR2b-
Expressing BaF3 Cells
(A and B) Binding of FGFR2b and FGFR1b (A) or FGF10 (B) to immobilized GAGs. FGFR2b, but not FGF10, specifically binds to immobilized 3st3-HS. ELISA
assays were performed in triplicate and repeated at least three times. Error bars represent SEM. 2,6S-Hep, heparin decasaccharides.
(C) 3-O-HS increases the amount of FGF10 immunoprecipitated with FGFR2b. The intensity of the protein bands was normalized to FGFR2b and shown as a fold
change in ratio of FGF10/FGFR2b. The graphs represent three experiments combined, and the blots are from a representative experiment.
(D) BaF3 cells expressing FGFR2bor FGFR1bwere incubatedwith 25 nMGAGs (chondroitin sulfate A [CS], heparin, HS, 3st1-HS, or 3st3-HS) and 50 nMFGF10 or
5nM FGF1. After 40 hr, the relative cell proliferation (A490) was determined. Data were normalized to FGFR2b-BaF3 cells treated with FGF10 or FGF1 and heparin.
Error bars show SEM. ANOVA; *p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S2.
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binding to FGFR2b, which may affect downstream outcomes.
To determine whether 3-O-HS specifically enhances FGFR2b-
dependent proliferation, we used BaF3 cell assays. These cells
do not express endogenous HS or FGFRs, and they do not pro-
liferate in response to FGF or heparin alone (Zhang et al., 2006).
Proliferation of FGFR2b- and FGFR1b-expressing BaF3 cells
was compared following incubation with either FGF10 or FGF1
and 3-O-HS, using heparin and chondroitin sulfate as positive
and negative controls, respectively. With FGF10 treatment,
both 3st1-HS and 3st3-HS increased FGFR2b-BaF3, but not
FGFR1b-BaF3 cell proliferation, compared to HS, with 3st3-HS
having the greatest increase (70% of heparin) (Figure 3D). With
FGF1 treatment, the proliferation of FGFR1b-BaF3, FGFR2b-
BaF3, and FGFR3c-BaF3 cells was similar with either 3-O-HS
or HS (Figures 3D and S2), suggesting the response to 3-O-HS
is both receptor and growth factor dependent.
3-O-HS/FGF10/FGFR2b Increases SMG Epithelial Cell
Proliferation and Regulates FGFR2b-Dependent Gene
Expression
To confirm that 3-O-HS also elicits an FGF10-dependent mitotic
response in SMG epithelium, we measured changes in epithelial666 Developmental Cell 29, 662–673, June 23, 2014 ª2014 Elsevier Imorphogenesis and proliferation after the addition of either
3st1-HS or 3st3-HS compared to HS. The addition of 3st3-HS
increased epithelial morphogenesis more than 3st1-HS (Fig-
ure 4A). Morphogenesis was expressed as a morphogenic
index (end bud number3width3duct length, in a.u.) (Figure 4A).
The addition of 3st3-HS also had a greater effect (2-fold
compared to HS) than 3st1-HS on proliferation, which was quan-
tified using 50-ethynyl-20-deoxyuridine (EdU) labeling (Figure 4B).
To confirm that this proliferation was MAPK dependent (as
suggested in Figure 2), we measured p42/44MAPK downstream
of 3-O-HS after 1 and 24 hr. Both 3-O-HS increased p42/
44MAPK compared to HS within 1 hr, and this was maintained
at 24 hr. Again, the increase with 3st3-HS was greater than
with 3st1-HS (Figure 4C).
We then measured gene expression downstream of 3-O-HS
treatment. Both 3st1-HS and 3st3-HS specifically increased
Hs3st1, Hs3st3a1, and Hs3st3b1, but not the other HS sulfo-
transferases (Figure 4D), suggesting that positive autocrine feed-
back increased 3-O-HS. In addition, 3-O-HS increased the
expression of genes downstream of FGFR2b signaling: Etv4,
Etv5, Myc, and Ccnd1 as well as Kit and Kitl. Although 3st1-HS
and 3st3-HS affected similar genes, 3st3-HS had a greater effect
on expression. To confirm that this occurs in other systems, wenc.
Figure 4. 3-O-Sulfated-HS Increases
FGF10-Dependent Epithelial Morphogen-
esis by Increasing Proliferation and
FGFR2b-Downstream Gene Expression
(A) FGF10-cultured E13 SMG epithelia were
treated with HS, 3st1-HS, or 3st3-HS for 28 hr.
3st3-HS increased end bud morphogenesis of
FGF10-treated epithelium compared to HS (con-
trol). Morphogenic index (end bud number 3
width 3 duct length, in a.u.) increases with addi-
tion of 3-O-HS. Scale bar, 50 mm.
(B) Single confocal sections showing cell prolifer-
ation (red) in epithelia cultured for 28 hr. Quantifi-
cation of fluorescence intensity normalized to total
nuclei staining and expressed as a ratio to the HS-
treated epithelia. At least five epithelia/conditions
were used for quantification from three indepen-
dent experiments. Scale bar, 10 mm.
(C) 3st3-HS increased MAPK signaling within 1 hr
and both 3st-HSs maintained it at 24 hr in FGF10-
cultured epithelia. Band intensity of phosphory-
lated MAPK (pMAPK) was normalized to total
MAPK and expressed as a fold change in ratio
compared to HS. The graphs are three experi-
ments combined, and the blots are from a repre-
sentative experiment.
(D) Gene expression was measured by qPCR and
normalized to epithelia cultured for 28 hr with HS
and Rps29.
Error bars represent SEM. ANOVA; *p < 0.05, **p <
0.01, and ***p < 0.001. See also Figure S3.
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ure S3). Similar to SMGs, the 3st3-HS increased both morpho-
genesis and the expression of FGFR2b-dependent transcription
factors involved in lung end bud progenitor development: Etv5,
Sox9, and Id2 (Lombaert et al., 2013; Rock and Hogan, 2011).
Taken together, these data suggest that 3-O-HS increases and
maintains FGFR2b-dependent signaling and proliferation of
end bud progenitors.
Knockdown of Hs3sts Reduces FGF10/FGFR2b-
Dependent Growth, and Both Are Rescued with
Exogenous 3-O-HS
Next, we predicted that reducingHs3st gene expression by RNAi
would reduce FGFR2b-dependent epithelial proliferation. We
used at least two different small interfering RNAs (siRNAs) for
each isoform, but the knockdown of individual Hs3st3 isoforms
or Hs3st1 did not affect morphogenesis (data not shown).
Therefore, we designed an siRNA that targeted common regions
of the Hs3st3a1, Hs3st3b1, and Hs3st6 isoforms and pooled it
with one targeting Hs3st1. Together they reduced epithelial
morphogenesis and Hs3st expression (Figures 5A and 5B). The
siRNAs reduced Hs3st1, Hs3st3a1, Hs3st3b1, and Hs3st6, but
not the other HS sulfotransferases such as Ndst1, Hs2st1, or
Hs6st1 (Figure 5C). Hs3st knockdown also reduced expression
of the Etv4, Etv5, Ccnd1, Kit, and Kitl (Figure 5C), consistent
with 3-O-HS being involved in FGF10/FGFR2b signaling and
proliferation of KIT+ progenitors. We predicted that exogenous
3-O-HS would rescue the effects of knocking down Hs3st
expression and increase FGFR2b-dependent proliferation. We
added HS to control siRNA-treated epithelium at a dose thatDeveldid not increase proliferation (Figures 5D and 5E). However,
similar concentrations of both 3st1-HS and 3st3-HS rescued
morphogenesis in Hs3st-siRNA-treated epithelium compared
to HS alone. Despite similar concentrations, 3st3-HS had greater
effects (Figures 5D and 5E) and also overcame the effects of
siRNA and increased the expression of Hs3st1, Hs3st3a1, and
Hs3st3b1 (Figure 5F). Together, these data show that 3-O-
sulfated HS controls FGF10/FGFR2b-dependent proliferation
and that exogenous 3-O-HS increases Hs3st gene expression
to overcome the effects of the siRNA in culture. Overall, our
data suggested that 3st3-HS might be a tool to specifically in-
crease FGFR2b-dependent proliferation and expand KIT+
progenitors.
3st3-HS Increases Endogenous 3-O-Sulfated HS and
Increases FGF10/FGFR2b Binding to the Epithelium
We next confirmed that treatment with 3st3-HS also increased
the endogenous 3-O-sulfated HS on the epithelium by staining
with gD1. An increase in gD1 bindingwas detected on epithelium
treated with 3st3-HS compared to control HS (Figure 6A). In
addition, a ligand and carbohydrate engagement (LACE) assay
was performed with recombinant FGF10 and FGFR2b-Fc to
determine whether the increase in endogenous gD1-binding
HS also resulted in increased binding of the FGF10/FGFR2b
complex, which was detected with anti-human-Fc antibodies.
Indeed, an increase in FGF10/FGFR2b assembly was detected
on epithelia treated with 3st3-HS compared to HS (Figure 6B).
These data are consistent with the hypothesis that an increase
in endogenous 3-O-sulfated HS increases FGF10/FGFR2b
signaling.opmental Cell 29, 662–673, June 23, 2014 ª2014 Elsevier Inc. 667
Figure 5. Knockdown of Hs3sts Decreases
Epithelial Morphogenesis and Hs3st
Expression, Which Are Both Rescued by
Exogenous 3st3-HS
(A) Light micrographs of FGF10-cultured E12 SMG
epithelia were treated for 40 hr with nonsilencing
(NS) or Hs3st siRNA. Scale bar, 50 mm.
(B) Quantification of epithelial morphogenesis
after 40 hr of siRNA transfection. Knockdown of
the Hs3sts inhibited branching compared to NS-
siRNA. Error bars represent SEM. ANOVA; ***p <
0.001, compared to control.
(C) Knockdown of Hs3sts decreased expression
of Etv4, Etv5, Ccnd1, Myc, Kit, and Kitl. Gene
expression was measured by qPCR and normal-
ized to NS-siRNA (dotted line). Error bars repre-
sent SEM. Student’s t test; *p < 0.05, **p < 0.01,
and ***p < 0.001.
(D) Light micrographs of FGF10-cultured E12 SMG
epithelia were treated with NS or Hs3st siRNA.
Exogenous HS, 3st1-HS, or 3st3-HSwas added to
these cultures following 16 hr of siRNA treatment.
Scale bar, 50 mm.
(E) Quantification of epithelial morphogenesis after
40 hr of siRNA transfection. Error bars represent
SEM. ANOVA; ***p < 0.001, compared to epithelia
treated with NS and HS.
(F) Gene expression of Hs3st1, Hs3st3a1, and
Hs3st3b1 is partially restored by 3st1-HS and
3st3-HS. Gene expression was measured by
qPCR and normalized to NS-siRNA (dotted line).
Error bars show SD.
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KIT+FGFR2b+ Progenitors
Because combined KIT/FGFR2b signaling increases the expan-
sion of KIT+FGFR2b+K14+ epithelial end bud progenitors (Lom-
baert et al., 2013), we predicted that exogenous 3st3-HS would
specifically enhance their expansion. We immunostained
epithelia treated with 3st3-HS or HS for KIT, CCND1, Ki67,
K14, and K19 (Figure 6C). 3st3-HS-treatment increased staining
compared to HS for KIT, K14, and the proliferative markers
CCND1 and Ki67 (Figure 6C, top and middle). 3st3-HS did not
affect staining of K19, a marker of ductal cells (Figure 6C,
middle). We further confirmed that 3st3-HS-treated epithelial
KIT+ progenitors expressed FGFR2b (Figure 6C, bottom). A pro-
file plot shows that both KIT and FGFR2b localize near the mem-
brane at a calculated overlap coefficient of r = 0.54 ± 0.015.
Because KIT+FGFR2b+ progenitors are present in the adult
SMG, we asked whether 3-O-HS expanded them in vitro, which
is an important step to obtain more progenitors for transplanta-
tion. Thus, we used in vitro spheroid culture of adult SMG pro-668 Developmental Cell 29, 662–673, June 23, 2014 ª2014 Elsevier Inc.genitors, termed salispheres, as pre-
viously used to enrich for KIT+
progenitors for autologous transplanta-
tion to regenerate irradiation-damaged
salivary glands (Lombaert et al., 2008).
The addition of 3st3-HS and FGF10
increased the number and size of
salispheres by day 3, an indicator of
increased progenitor numbers, com-pared to HS treatment (Figure 6D). Remarkably, even at 6 days
of culture, the salispheres contained cells expressing KIT that
were actively proliferating (CCND1+) (Figure 6D). Together,
these data indicate that exogenous 3st3-HS expands and pro-
longs the proliferation of adult KIT+FGFR2b+ progenitors.
DISCUSSION
Here we propose a model where 3-O-HS stabilizes FGF10/
FGFR2b complex formation to increase FGFR2b-dependent
MAPK signaling, gene expression, and proliferation (Figure 7).
The proliferative response of KIT+FGFR2b+ progenitors is
enhanced and maintained via rapid feedback to increase Hs3st
expression. Thus, 3-O-HS provides a cellular mechanism to
respond to a specific growth factor and amplify that response
to expand specific progenitors. The function of specific HSmod-
ifications fine-tuning growth factor signaling via regulation of HS
biosynthetic enzymes is an emerging paradigm supported by
other studies. For example, a 6-O-endosulfatase fine-tunes
Figure 6. 3-O-Sulfated-HS Increases Endogenous 3-O-HS, FGF10/FGFR2b-Fc Binding, Proliferation, and KIT Expression
(A–C) FGF10-cultured E13 SMG epithelia treated with HS or 3st3-HS for 28 hr were stained. Staining with gD1 (green) and ECAD (red) (A) or with FGF10/FGFR2b-
Fc (LACE assay, green) and ECAD (red) (B). (C) Top panels, CCND1, KIT (green), and DAPI (blue); middle panels, K14 (red), K19 (green), and Ki67 (blue); and
bottom panels, FGFR2 (red), KIT (green), and DAPI (blue). The profile plots (lower right) quantify the relative intensity of the KIT and FGFR2 protein distribution at
the position along the white dotted line in the overlay image. The fluorescence signal from anti-KIT-Cy2 colocalized with anti-FGFR2-Cy3 immunofluorescence
signal with an overlap coefficient of r = 0.54 ± 0.015. Images are 2 mm confocal sections. Scale bars, 10 mm except 2 mm in lower right image. Quantification of
fluorescence intensity normalized to total nuclei staining and expressed fold increase compared to HS-treated epithelia. At least five epithelia from three in-
dependent experiments were used for quantification.
(D) 3-O-HS treatment increases salisphere size (top). Quantification of the number and diameter of salispheres formed after 3 days. 3-O-HS increases both the
count and size of salispheres compared to HS. Confocal sections of salispheres cultured for 6 days with HS or 3st3-HS stained with KIT (green, middle) and
CCND1 (green, bottom). Quantification of KIT andCCND1 fluorescence intensity normalized to total nuclei staining and expressed as a fold increase compared to
HS-treated salispheres. At least five salispheres from each of three independent experiments were used for quantification. Scale bar, 10 mm.
Error bars represent SEM. Student’s t test; *p < 0.05, **p < 0.01, and ***p < 0.001.
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and this involves regulation of the sulfatase expression
pattern by epidermal growth factor receptor signaling (Wojcinski
et al., 2011). In addition, during lacrimal gland development N-
sulfation potentiates FGF10/FGFR2 interactions and Shp2/ErkDevelsignaling, which feedback to regulate Ndst expression (Pan
et al., 2008).
The 3-O-sulfotransferase family creates the least abundant
type of sulfate modification, making it difficult to isolate and
analyze these rare 3-O-sulfated products. Currently, there is aopmental Cell 29, 662–673, June 23, 2014 ª2014 Elsevier Inc. 669
Figure 7. Rapidly Altering 3-O-Sulfation Provides a Cellular Mecha-
nism to Modulate the Response to FGFR2b Signaling and Control
Progenitor Expansion
Model showing that 3-O-HS rapidly increases 3-O-sulfotranseferase expres-
sion, 3-O-sulfated HS on the epithelium and FGF10/FGFR2b complex
formation, MAPK signaling, gene expression of FGFR2b signaling targets,
proliferation genes, and Kit and its ligand, which expands the KIT+FGFR2b+
progenitors.
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only recently the enzyme that specifically removes 3-O-sulfa-
tion, arylsulfatase G, was identified (Kowalewski et al., 2012).
Research has focused on Hs3st1 because it forms the AT-
binding HS epitope, but here we used a bioengineered 3-O-
HS to investigate Hs3st3 function. Treatment of kidney HS,
which has low endogenous 3-O-sulfation, with recombinant
3-O-sulfotransferases enzymes added approximately two extra
sulfates/HS chain and allowed us to probe specific functions of
3st3-HS. Although HS modified by both Hs3st1 and Hs3st3
have some similar functions, the specific epitopes on these
HS chains responsible for specific activity in a particular assay
remain to be defined, and epitopes may have some overlap-
ping functions in specific assays, or multiple epitopes may in-
fluence a particular function. Our data support the hypothesis
that the sulfate pattern, and not just overall charge, is critical
for specific HS functions and fine-tuning of growth factor
signaling.
The rapid response to 3-O-HS in KIT+FGFR2b+ progenitors
may be due to a number of factors. First, we show that 3-O-
HS binds FGFR2b, which stabilizes the FGF10/FGFR2b
complex, and this may affect the FGF binding affinity. The
binding affinity of FGF10 to HS and FGFR2b are crucial for
its biological outcome. A mutation in the HS binding site of
FGF10 reduces its binding to HS, converting FGF10 into a func-
tional mimic of FGF7, in terms of organ morphogenesis and
global gene expression, whereas a mutation in FGF10 binding
site for FGFR2b reduces the overall growth response (Makar-
enkova et al., 2009). Second, the binding of FGF10 to FGFR2b
increases endocytic recycling of FGFR2b, which correlates with
higher mitogenic activity, whereas the binding of FGF7 results
in receptor ubiquitination and degradation (Belleudi et al.,
2007). We speculate that formation of 3-O-HS/FGF10/FGFR2b670 Developmental Cell 29, 662–673, June 23, 2014 ª2014 Elsevier Icomplexes combined with endocytic FGFR recycling would in-
crease and maintain a mitotic response in KIT+FGFR2b+
progenitors.
We propose that a similar mechanism involving 3-O-HS may
exist in other organs that develop via FGFR2b-dependent
branching morphogenesis, such as the lung, kidney, mammary
gland, pancreas, lacrimal gland, and prostate gland (Davies,
2002; Hogan and Kolodziej, 2002; Tsau et al., 2011). Because
multiple Hs3st genes are expressed in a variety of tissues (Fig-
ure S1D), some redundancy or overlap in their function may
exist. However, for the lung, we show that 3-O-HS has similar
effects on epithelial end buds (Figure S3), which also express
KIT+FGFR2b+ progenitors (Lombaert et al., 2013). Lacrimal
gland end bud proliferation is dependent on FGF10 and
NDST1 (Pan et al., 2008). However, NDST1 acts early in HS
biosynthesis, and the effects of reducing N-sulfation on 3-O-sul-
fation were not examined. Thus, unique HS modifications may
alter tissue-specific progenitor expansion.
Because Hs3sts modulate growth factor responses, it is not
surprising that they influence tumor progression (Bishop et al.,
2007). Extensive DNA methylated sites are present in HS3ST1,
HS3ST3A1, and HS3ST6 in H-HEMC-SS chondrosarcoma cells
that repressHS3ST expression and enhance the invasive pheno-
type (Bui et al., 2010). Hypermethylation of Hs3st2 also reduces
its expression and occurs in a wide range of human cancers,
including breast, colon, lung, and pancreatic (Miyamoto et al.,
2003). Thus, tumorogenesis correlates with reduced HS3ST
enzymes, which may disrupt the specificity and fine-tuning of
growth factor responses. It will be interesting to determine
whether 3-O-HS can modify growth factor responses of cancer
cells.
Apart from expanding progenitors, HS sulfation also influ-
ences progenitor fate (Cool and Nurcombe, 2006). Studies of
mouse embryonic stem cells (ESCs) with HS biosynthetic en-
zymes deleted show there are effects on pluripotency and
FGF- and bone morphogenic protein (BMP)-dependent differ-
entiation (Kraushaar et al., 2012; Lanner et al., 2010). Yet,
in vitro addition of HS saccharides of specific length and sulfa-
tion directed BMP-dependent ESC differentiation and FGF-
dependent neuronal cell differentiation (Holley et al., 2011;
Pickford et al., 2011). Additionally, an embryonic form of HS,
whose HS structure was not identified, enhanced the multipo-
tency of human mesenchymal stem cells (Helledie et al.,
2012). Our data show that 3-O-HS can expand both fetal and
adult KIT+FGFR2b+ progenitors in vitro, but it is unclear
whether it influences their cell fate or potency. Other HS-
dependent growth factor pathways may be involved. Addition-
ally, heparanases or sheddases, which can release 3-O-HS
from the KIT+ progenitor surface, may also influence the fate
of adjacent progenitors.
An important question remains as to the identity of core pro-
teins that have 3-O-HS added to them. Our FACS data show
increased, but not significant, expression of syndecan 4 (Sdc4)
in KIT+ progenitors (Figure S1A). Our temporal expression
data, however, show that Hs3st gene expression increases
within 1–2 hr, but that the increase in core protein expression
occurs later, after 6 hr (data not shown). This suggests the cell
could first increase enzyme synthesis to modify the pool of HS
being synthesized, but then also upregulate specific corenc.
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levels of HS3ST enzymes that modify only a portion of an excess
precursor pool (Shworak et al., 1996; Yabe et al., 2001).
Moreover within a clonal cell line, HS structure appears to be
equivalent across multiple core proteins (Shworak et al., 1994).
It is unclear whether syndecan 4 HS is specifically 3-O-sulfated
in response to FGF10, and the dynamics of HSPG core synthesis
and coordination with changes in the HS biosynthetic program
require further investigation.
In conclusion, we show that the fine-tuning of HS biosynthesis
at its terminal step, by adding the least abundant sulfate group,
ensures a rapid and specific response to FGF10 signals. Auto-
crine feedback, from 3-O-HS/FGF10/FGFR2b signaling, upregu-
lates Hs3st3 expression, to increase 3-O-HS and maintain the
proliferation of epithelial KIT+FGFR2b+ progenitors.We propose
that 3-O-HS may increase the expansion of KIT+FGFR2b+ pro-
genitors from patient biopsies in vitro for use in autologous pro-
genitor transplantation to regenerate organs.
EXPERIMENTAL PROCEDURES
Ex Vivo Organ Culture and FACS
All protocols involving mice were approved by the NIH Animal Care and Use
Committee. Fetal SMGor lung organ cultures and FACS analysis were recently
described in Lombaert et al. (2013). Single-cell suspensions of SMGs were
incubated with anti-KIT-APC (BD Pharmingen) and anti-ECAD-PE (R&D Sys-
tems), and sorted on a BD FACSAria II cell sorter (BD Biosciences).
Labeling of HS
AT488 was prepared as described previously (Girardin et al., 2005). We used
HSV-1gD, which has a truncated ectodomain at residues 285 and binds to
receptors in vitro with a 100-fold increased affinity than full-length ectodo-
mains (Krummenacher et al., 1999). For details, see Supplemental Experi-
mental Procedures.
Preparation of 3-OST-Modified HS
The 3-OST-modified HS was prepared by incubating HS (from bovine kidney)
and purified 3-OST-1 and 3-OST-3 enzymes as described previously (Xu et al.,
2008). Briefly, 10 mg of HS, 100 mM 30-phosphoadenosine-50-phosphosulfate
(PAPS), 50 mM 2-(N-morpholino)ethanesulfonic acid (pH 7.0), 10 mM MnCl2,
5 mM MgCl2, and 1% Triton X-100 (v/v), and 4 mg of 3-OST-1 or 3-OST-3
protein was incubated in 100 ml at 37C for 1 hr. The 3-OST-modified HS
was isolated by a diethylaminoethyl-Sephacel chromatography. To monitor
the extent of 3-O-sulfation, 3-O-[35S] sulfated HS was prepared using [35S]
PAPS (specific activity 6,500 cpm/nmol, 100 mM). Disaccharide analysis of
the modified HS and binding to AT and gD1 were described previously (Xu
et al., 2008). Typically, approximately two 3-O-sulfo groups per polysaccha-
ride were incorporated.
qPCR
Real-time PCR was performed as described previously (Patel et al., 2008).
Briefly, cDNA was generated from DNase-free RNA, amplified, and gene
expression was normalized to the housekeeping gene Rps29. The reactions
were run in triplicate, and the experiment was repeated three times.
In Situ Hybridization
Digoxigenin (DIG)-labeled RNA probes were prepared using the appropriate
RNA polymerase using the DIG RNA labeling kit (Roche Applied Science)
according to the manufacturer’s instructions. In situ hybridization was
described previously (Patel et al., 2008).
Pull-Down Assays
Equal molar concentrations (5 nM) of recombinant FGF10, recombinant
FGFR2b, and HS were incubated together for pull-down assays as describedDevelpreviously (Sugaya et al., 2008), with slight modification. For details, see Sup-
plemental Experimental Procedures.
FGFR2b and FGF10/GAG Binding Assay
An enzyme-based assay was performed to determine the binding of FGFR2b
or FGF10 to 3-O-HS using 96-well heparin/GAG binding plates (Iduron),
according to the manufacturer’s protocol. FGFR2b and FGF10 binding was
detected as described in the Supplemental Experimental Procedures.
RNA Interference and HS Rescue
At least two siRNAs targeting each Hs3st gene were purchased (QIAGEN or
Dharmacon). The siRNA sequences used were as follows: TCA ACC GCA
AGT TCT ACC AGA to target Hs3st3a1, Hs3st3b1, and Hs3st6, referred as
Hs3st3a-3b-6 (Dharmacon); CAC CTC CTT GTC AAA TCT ATA to target
Hs3st1; and AAT TCT CCG AAC GTG TCA CGT, the nonsilencing control
(both QIAGEN). Isolated epithelial rudiments cultured in laminin-111 gel were
transfected with a combination of Hs3st1 and Hs3st3a-3b-6 (100 nM each)
siRNA in 200 ml of culture medium using Oligofectamine (Invitrogen) as
described previously (Rebustini et al., 2007). HS or 3-O-HS (0.5 mg/ml or
35 nM) was added following 16 hr of siRNA transfection. Gene knockdown
was measured by qPCR analysis after 40 hr culture.
Immunofluorescence Analysis and Detection of Cell Proliferation
Whole-mount immunofluorescence was performed as described previously
(Rebustini et al., 2012). SMG epithelial proliferation was detected using
Click-iT EdU Alexa Fluor 488 proliferation kit (Invitrogen) according to the
manufacturer’s protocols. Binding of labeled AT488 or gD1 was performed
as described in the Supplemental Experimental Procedures. Images were
obtained using a Zeiss LSM 710 confocal microscope.
BaF3 Proliferation Assays
BaF3 cells stably expressing the FGFR splice isoforms (FGFR1b, FGFR2b,
FGFR2c, and FGFR3c) were kindly provided by Dr. David Ornitz (Washington
University) and maintained as described previously (Ornitz et al., 1996). For a
detailed protocol, see Supplemental Experimental Procedures.
Salisphere Assay
This assay was performed as described previously (Lombaert et al., 2008),
with minor modifications to the culture medium. Carbachol (10 nM), Y-27632
rock inhibitor (5 mM) (Calbiochem), and FGF10 (50 ng/ml) with or without HS
or 3st3-HS (both 50 ng/ml, 3.6 nM) were also supplemented to the culture
medium. At day 3, the salispheres were counted and photographed to mea-
sure their size. The salispheres were cultured for 6 days and the either lysed
for RNA extraction or stained for KIT and CCND1.
Statistical Analysis
Data were log transformed before all statistical analysis. We used Prism 6
software (GraphPad). Student’s t test was used to compare two different
groups; one-way ANOVA with post hoc Dunnett’s test was used to compare
more than two experimental groups; and multiple unpaired t tests were
analyzed by a false discovery rate approach, where Q, the acceptable rate
for false discoveries, was set to 5%. Graphs show the mean ± SEM for each
group from three or more experiments.
SUPPLEMENTAL INFORMATION
Supplementary Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.devcel.2014.04.024.
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